会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • Orally bioavailable CCI-779 formulations
    • 口服生物可利用的CCI-779制剂
    • US20080161336A1
    • 2008-07-03
    • US12075520
    • 2008-03-12
    • Joseph P. BoniMuhammad AshrafEric J. Benjamin
    • Joseph P. BoniMuhammad AshrafEric J. Benjamin
    • A61K31/44A61K31/19
    • A61K9/2095A61K9/146A61K9/2027A61K31/4745
    • A CCI-779 oral dosage form is provided in which, after oral administration to a subject, the CCI-779 has a whole blood peak concentration (Cmax) of 5.4±1.8 ng/mL and an area under the curve (AUC) of about 66± about 22 ng-hr/ml and the sirolimus has a Cmax of 18.7±9.6 ng/mL and an AUC of about 600± about 228 ng-hr/ml, for a 25 mg unit dose of CCI-779. Another CCI-779 oral dosage form is provided which, after oral administration thereof to a subject, the CCI-779 has a Cmax of 5.7±1.7 ng/mL and an AUC of about 60± about 20 ng-hr/ml and the sirolimus has a Cmax of 17.1±8.1 ng/mL and an AUC of about 548± about 187 ng-hr/ml in whole blood, for a 25 mg unit dose of CCI-779. Products containing these oral dosage forms, and methods of use thereof, are also described.
    • 提供CCI-779口服剂型,其中口服给予受试者后,CCI-779具有5.4±1.8ng / mL的全血峰浓度(C max)和面积 在约66±约22ng-hr / ml的曲线(AUC)下,西罗莫司的C max最大值为18.7±9.6ng / mL,AUC为约600±约228ng-hr / ml,用于25mg单位剂量的CCI-779。 提供了另一种CCI-779口服剂型,其在口服给予受试者后,CCI-779的C max≥5.7±1.7ng / mL,AUC为约60±20 ng-hr / ml,并且西罗莫司在全血中的C max最大值为17.1±8.1ng / mL,AUC为约548±约187ng-hr / ml,对于25mg单位剂量 的CCI-779。 还描述了含有这些口服剂型的产品及其使用方法。